RAD-140 vs Testosterone: SARMs vs TRT — A Clinical Comparison

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

This article clinically compares RAD-140 (a SARM) and Testosterone Replacement Therapy (TRT), detailing their mechanisms, benefits, dosing, and side effects. It highlights TRT as the medically sanctioned treatment for low testosterone, contrasting it with the investigational and unregulated nature of RAD-140.

# RAD-140 vs Testosterone: SARMs vs TRT — A Clinical Comparison

By Adam Maggio

In the pursuit of enhanced physical performance, muscle growth, and improved well-being, individuals often explore various compounds designed to influence the body's hormonal systems. Among the most discussed are Selective Androgen Receptor Modulators (SARMs) like RAD-140 (Testolone) and traditional Testosterone Replacement Therapy (TRT). While both aim to exert anabolic effects, their mechanisms, safety profiles, and legal statuses differ significantly. This article provides a comprehensive clinical comparison to help you understand the nuances of each.

What is RAD-140 (Testolone)?

RAD-140, also known as Testolone, is an investigational Selective Androgen Receptor Modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic (masculinizing) side effects. The 'selective' aspect means they are designed to target androgen receptors in specific tissues, such as muscle and bone, while minimizing activity in others, like the prostate and sebaceous glands.

Mechanism of Action

RAD-140 works by selectively binding to androgen receptors (ARs) in the body. Unlike traditional anabolic steroids, which activate ARs throughout the body indiscriminately, RAD-140 is hypothesized to have a tissue-selective action. This selectivity is intended to promote anabolic effects in muscle and bone tissue, leading to increased muscle mass and bone density, while theoretically reducing the androgenic side effects associated with testosterone, such as prostate enlargement or hair loss. Preclinical studies have shown RAD-140 to be a potent, orally bioavailable, nonsteroidal SARM with high affinity and specificity for ARs [PMID: 24900290]. It has also demonstrated neuroprotective effects in cultured neurons and animal models, suggesting potential benefits for neural health [PMID: 24428527].

Benefits

Based on preclinical research and anecdotal reports (as human clinical data is limited and ongoing), potential benefits of RAD-140 include:

Increased Muscle Mass and Strength: The primary appeal of RAD-140 is its ability to promote significant gains in lean muscle mass and strength, similar to testosterone but with potentially fewer androgenic side effects.

Bone Density Improvement: Like other SARMs, RAD-140 may contribute to increased bone mineral density, which could be beneficial for conditions like osteoporosis.

Neuroprotective Properties: Early research suggests RAD-140 may protect brain cells from damage, potentially offering therapeutic avenues for neurodegenerative diseases like Alzheimer's [PMID: 24428527].

Fat Loss: While not a direct fat burner, increased muscle mass can lead to a higher metabolic rate, aiding in fat reduction.

Dosing Protocols

It is crucial to note that RAD-140 is an investigational compound, and there are no FDA-approved dosing guidelines for human use. Most dosing information is derived from preclinical animal studies or anecdotal reports from the research chemical community. Preclinical studies in rats have shown efficacy at doses ranging from 0.03 mg/kg to 0.3 mg/kg orally for anabolic effects [PMID: 24900290]. For neuroprotective effects, 1 mg/kg was administered in rat models [PMID: 24428527]. Human anecdotal dosages typically range from 10-30 mg per day, often cycled for 8-12 weeks. However, these are not medically sanctioned recommendations and carry inherent risks.

Side Effects

Despite its selective nature, RAD-140 is not without potential side effects, especially when used outside of controlled clinical settings. These can include:

Testosterone Suppression: While designed to be selective, RAD-140 can still suppress natural testosterone production, leading to symptoms of low testosterone after a cycle, necessitating post-cycle therapy (PCT).

Liver Toxicity: Some case reports have indicated potential for drug-induced liver injury with SARM use, including RAD-140, particularly at higher doses or prolonged use.

Hair Loss/Acne: Although less common than with traditional steroids, some users report androgenic side effects like accelerated hair loss or acne.

Cholesterol Imbalance: SARMs can negatively impact lipid profiles, leading to decreased HDL (good cholesterol) and increased LDL (bad cholesterol).

Mood Swings/Aggression: Alterations in hormone levels can sometimes lead to mood disturbances.

Improved Libido and Sexual Function: One of the most common and significant benefits is the restoration of sex drive and improvement in erectile function.

Increased Muscle Mass and Strength: Testosterone is a potent anabolic hormone, and TRT can lead to increased lean muscle mass and strength, along with reduced fat mass.

Enhanced Bone Density: TRT helps improve bone mineral density, reducing the risk of osteoporosis and fractures.

Improved Mood and Energy Levels: Many men report significant improvements in mood, reduction in irritability, and increased energy and vitality.

Cognitive Function: Some studies suggest TRT may improve certain aspects of cognitive function, particularly in older men with low testosterone.

Cardiovascular Health: Recent large-scale studies have indicated that TRT, when properly managed, may not increase cardiovascular risk and could even be beneficial in some populations [PMID: 32068334].

Intramuscular Injections: Testosterone cypionate or enanthate, typically 50-200 mg every 1-2 weeks [PMID: 28078214].

Transdermal Gels/Patches: Applied daily, delivering 25-100 mg of testosterone per day [PMID: 28078214].

Subdermal Pellets: Implanted every 3-6 months, releasing testosterone slowly [PMID: 28078214].

Nasal Gel: Administered three times daily, delivering a lower daily dose [PMID: 28078214].

Erythrocytosis (Increased Red Blood Cell Count): This can increase the risk of blood clots and is a common side effect, often managed by dose adjustment or phlebotomy.

Prostate Enlargement (BPH): TRT can exacerbate benign prostatic hyperplasia (BPH) symptoms in older men, though it does not cause prostate cancer.

Acne/Oily Skin: Androgenic effects can lead to skin issues.

Sleep Apnea: TRT can worsen sleep apnea in some individuals.

Fluid Retention: Mild fluid retention can occur.

Gynecomastia: Due to the conversion of testosterone to estrogen, some men may experience breast tissue enlargement.

Infertility: Exogenous testosterone suppresses natural testosterone production and spermatogenesis, leading to temporary or, in rare cases, permanent infertility.

Who is TRT Best For?

TRT is best for men with clinically diagnosed hypogonadism who experience symptoms of low testosterone and have confirmed low serum testosterone levels through blood tests. It is a medical treatment prescribed and monitored by a healthcare professional to improve quality of life and address health issues stemming from testosterone deficiency.

Side-by-Side Comparison: RAD-140 vs. Testosterone

| Feature | RAD-140 (Testolone) | Testosterone Replacement Therapy (TRT) |

| :------------------ | :---------------------------------------------------- | :------------------------------------------------------------------- |

| Type | Selective Androgen Receptor Modulator (SARM) | Bioidentical Hormone (Testosterone) |

| Mechanism | Selective AR agonist in muscle/bone; investigational | Direct replacement of endogenous testosterone; systemic AR activation |

| Primary Use | Investigational; anecdotal use for muscle growth, performance | Medically prescribed for hypogonadism (low T) |

| Legality | Research chemical (not approved for human use); WADA prohibited | Legal with prescription; FDA-approved medical treatment |

| Anabolic Effects| Potent, tissue-selective (preclinical) | Potent, systemic |

| Androgenic Effects| Designed to be minimal, but can occur (e.g., suppression) | Present (e.g., prostate, hair follicles, skin) |

| Estrogenic Effects| None directly; no aromatization | Present (via aromatization to estrogen) |

| Dosing | Anecdotal: 10-30 mg/day (cycled); no clinical guidelines | Individualized: Injections, gels, patches, pellets (medically supervised) |

| Side Effects | Testosterone suppression, potential liver toxicity, cholesterol imbalance, hair loss, acne | Erythrocytosis, BPH exacerbation, acne, sleep apnea, fluid retention, gynecomastia, infertility |

| Monitoring | None medically sanctioned | Regular blood tests (T, E2, hematocrit, PSA) |

| Long-Term Data | Very limited/none in humans | Extensive clinical data and long-term safety profiles |

RAD-140 vs. Testosterone: A Clinical Comparison

When comparing RAD-140 and Testosterone, it's essential to distinguish between an investigational compound and a medically established treatment.

Efficacy Comparison

Testosterone, as the body's natural androgen, has a well-understood and potent anabolic effect across various tissues. TRT effectively restores muscle mass, strength, bone density, and improves mood and libido in hypogonadal men. RAD-140, in preclinical studies, has shown promising anabolic activity, even demonstrating neuroprotective qualities [PMID: 24428527]. However, the extent to which these preclinical anabolic benefits translate to humans with a favorable risk-benefit profile, especially compared to testosterone, remains largely unproven in rigorous clinical trials.

Safety Profile Comparison

This is where the most significant divergence lies. TRT, when prescribed and monitored by a qualified physician, has a well-established safety profile. Potential side effects are known, manageable, and regularly monitored through blood work. In contrast, RAD-140, as a research chemical, lacks comprehensive human safety data. The long-term effects, optimal dosing for safety, and full spectrum of potential adverse reactions are largely unknown. Concerns about liver toxicity and significant testosterone suppression are particularly salient with SARM use outside of medical supervision.

Legality and Accessibility

Testosterone is a Schedule III controlled substance in the United States and requires a prescription for legal use. It is readily available through legitimate medical channels for individuals with a diagnosed medical need. RAD-140, on the other hand, is typically sold as a 'research chemical' and is not approved for human consumption. Its purchase and use for personal enhancement are legally ambiguous and carry significant risks due to unregulated manufacturing and unknown purity. It is also banned by major anti-doping agencies.

Clear Winner/Recommendation

For individuals with clinically diagnosed low testosterone and associated symptoms, Testosterone Replacement Therapy (TRT) is the unequivocal winner. It is a proven, medically supervised treatment with a well-understood safety profile and established benefits. The decision to undergo TRT should always be made in consultation with a healthcare professional.

For those without a medical diagnosis of hypogonadism seeking performance enhancement, neither option is without risk. However, RAD-140, as an unregulated research chemical, presents a far greater unknown risk profile. Its use is not medically sanctioned, and individuals expose themselves to potentially severe and unmonitored side effects. The allure of quick gains with SARMs often overshadows the significant health risks and legal ramifications.

Bottom Line

While both RAD-140 and Testosterone aim to influence the body's androgenic system, their applications, safety, and legality are vastly different. TRT is a legitimate medical treatment for a diagnosed condition, offering well-documented benefits under medical supervision. RAD-140, despite its theoretical tissue selectivity, remains an unapproved research chemical with limited human data and significant potential risks. Prioritizing health and s